Cargando…
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related...
Autores principales: | Albinger, Nawid, Hartmann, Jessica, Ullrich, Evelyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455322/ https://www.ncbi.nlm.nih.gov/pubmed/33753909 http://dx.doi.org/10.1038/s41434-021-00246-w |
Ejemplares similares
-
Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020) -
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021) -
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)